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Purpose
We investigated whether irinotecan plus capecitabine improved progression-free survival
(PFS) compared with capecitabine alone in patients with human epidermal growth factor 2
(HER2) negative and anthracycline and taxane pretreated metastatic breast cancer (MBC). 
Materials and Methods
A total of 221 patients were randomly assigned to irinotecan (80 mg/m2, days 1 and 8) and
capecitabine (1,000 mg/m2 twice a day, days 1-14) or capecitabine alone (1,250 mg/m2
twice a day, days 1-14) every 3 weeks. The primary endpoint was PFS.
Results
There was no significant difference in PFS between the combination and monotherapy arm
(median, 6.4 months vs. 4.7 months; hazard ratio [HR], 0.84; 95% confidence interval [CI],
0.63 to 1.11; p=0.84). In patients with triple-negative breast cancer (TNBC, n=90), the com-
bination significantly improved PFS (median, 4.7 months vs. 2.5 months; HR, 0.58; 95%
CI, 0.37 to 0.91; p=0.02). Objective response rate was numerically higher in the combination
arm, though it failed to reach statistical significance (44.4% vs. 33.3%, p=0.30). Overall sur-
vival did not differ between arms (median, 20.4 months vs. 24.0 months; p=0.63). While
grade 3 or 4 neutropenia was more common in the combination arm (39.6% vs. 9.0%),
hand-foot syndrome was more often observed in capecitabine arm. Quality of life measure-
ments in global health status was similar. However, patients in the combination arm showed
significantly worse symptom scales especially in nausea/vomiting and diarrhea.  
Conclusion
Irinotecan plus capecitabine did not prove clinically superior to single-agent capecitabine
in anthracycline- and taxane-pretreated HER2 negative MBC patients. Toxicity profiles of
the two groups differed but were manageable. The role of added irinotecan in patients with
TNBC remains to be elucidated.
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Introduction
Despite substantial progress in patient management over
the past few decades, metastatic breast cancer (MBC) is still
considered incurable. To date, the mainstay of treatment for
MBC is cytotoxic chemotherapy which has been proved to
prolong survival and improve quality of life (QoL) in 
patients with MBC [1]. Nevertheless, there are few alterna-
tives if patients show resistance to anthracycline- or taxane-
based regimens. Therefore, new treatment options are urgen-
tly needed, particularly for patients with heavily pretreated
refractory disease. 
Irinotecan is a topoisomerase I (Top1) inhibitory pro-drug
that is enzymatically converted to the active metabolite SN-
38 [2]. It preserves single-strand DNA breaks and binds to
Top1-DNA complexes during DNA replication and tran-
scription resulting in double-stranded DNA breaks and
eventual cell death [3]. Irinotecan has been used in conjunc-
tion with other chemotherapeutic agents to treat colorectal,
lung, and gastric cancers [4,5]. Specifically, irinotecan com-
bined with capecitabine or 5-fluorouracil has been widely 
accepted as the first line therapy in metastatic colorectal can-
cer, given its synergistic effects [4,6]. In breast cancer, its anti-
tumor activity has been assessed either in single-agent use
or in combination with other therapeutics. As monotherapy,
objective response rates (ORRs) have ranged from 14%-23%,
and median response duration was reported around 4.5
months in patients with heavily pretreated MBC [7]. Mean-
while, irinotecan when added to docetaxel, gemcitabine, or
cisplatin showed response rates of 31%-64% and median
time-to-progression of 6.7-8 months in patients with MBC
[8,9]. We previously conducted a phase II single-arm study
investigating the feasibility of using irinotecan plus
capecitabine (IX) in patients with anthracycline- and taxane-
pretreated MBC. As a result, ORR was 58.3% (95% confi-
dence interval [CI], 42.2 to 72.9), and median progression-
free survival (PFS) was 7.6 months (95% CI, 5.0 to 10.2) [10].
Toxicities of this combination were manageable and tolera-
ble: neutropenia  grade 3, 58.4%; febrile neutropenia 5.6%;
and grade 3 diarrhea, 2.8%. Based on these promising results,
a randomized, multicenter, and open-label phase III clinical
trial was conducted to determine whether irinotecan plus
capecitabine was superior to capecitabine alone in terms of
PFS for patients with anthracycline- and taxane-pretreated
MBC. 
Materials and Methods
1. Study design and patients
This open-label, multicenter, randomized phase III study
(PROCEED; Randomized Phase III trial of irinotecan plus
capecitabine versus capecitabine monotherapy in patients
with MBC previously treated with anthracycline and taxane)
was conducted at 10 sites in South Korea. Eligible patients
were  20 years old, with Eastern Cooperative Oncology
Group (ECOG) performance status scores of 0 or 1 and
human epidermal growth factor 2 (HER2)–negative MBC.
All participants had previously received anthracycline- and
taxane-based chemotherapies and no more than two previ-
ous cytotoxic regimens for their metastatic disease. Patients
who experienced disease recurrence within 1 year after com-
pletion of neo/adjuvant anthracycline- and taxane-based
chemotherapy were also eligible without any treatment for
their metastatic disease. Other inclusion criteria were as fol-
lows: (1) resolution of treatment-related toxicities to  grade
1, according to National Cancer Institute Common Terminol-
ogy Criteria for Adverse Events (NCI-CTCAE) ver. 3.0; (2)
adequate organ function; and (3) negative serum pregnancy
test. The main exclusion criteria were symptomatic brain
metastasis, uncontrolled infection, or serious medical prob-
lems such as heart failure, uncontrolled diabetes, or gastroin-
testinal problems with absorption. 
Patients were evenly randomized to either the irinotecan/
capecitabine combination (IX) or the single-agent capeci-
tabine (X) study arm. Randomization was stratified by hor-
mone receptor status and presence of visceral metastasis. The
primary study endpoint was PFS in the intention-to-treat
(ITT) population, with secondary endpoints of ORR, overall
survival (OS), and safety. 
2. Study treatment and assessment 
Irinotecan was administered intravenously at a dose of 80
mg/m2 over 90 minutes on days 1 and 8, and capecitabine
was given per oral as 1,000 mg/m2 dose twice daily on days
1-14 every 3 weeks. In the single-agent capecitabine arm, the
dosage was 1,250 mg/m2 twice daily on days 1-14 every 
3 weeks. To lessen irinotecan-induced toxicities, we concomi-
tantly administered urodeoxycholinic acid (200 mg three
times), sodium bicarbonate (1,000 mg twice), and magnesium
oxide (300 mg) for 3 days. Loperamide was used to manage
delayed diarrhea. Dose modifications were performed for
patients with toxicities with the same manner as that utilized
in the previous phase II clinical trial [10]. Capecitabine inter-
ruptions or adjustments to manage toxicities were permitted
at the physician’s discretion. Treatment was continued until
44 CANCER  RESEARCH  AND  TREATMENT
disease progression, unacceptable toxicities, or patient 
request for discontinuation. 
To assess tumors, the Response Evaluation Criteria in Solid
Tumors (RECIST) ver. 1.1 was applied at screening and every
6 weeks after treatment initiation. Adverse events (AEs) were
evaluated and recorded at baseline and throughout treat-
ment using the NCI-CTCAE ver. 3.0. The European Organi-
zation for Research and Treatment of Cancer (EORTC)
Quality of Life Core Questionnaire (QLQ-C30) was also 
administered to each patient at baseline and after every two
cycles of chemotherapy [11]. For this study, we used the 
Korean version of QLQ-C30 which has been validated [12].
3. Statistical analysis 
Prior data had provided a median PFS value for the control
arm of capecitabine monotherapy (X), which was 4.0 months
in a similar patient population [13,14]; and we anticipated a
median PFS of 6.0 months for combined irinotecan/capeci-
tabine treatment (IX). Patients would be randomized to each
group at a 1:1 ratio, necessitating a total enrollment of 200
patients for a power of 80%. The type I error probability 
associated with testing this null hypothesis was 0.05. Assum-
ing a withdrawal rate of 10%, a total patient accrual of 222
was warranted.
All patients participating in randomization were included
in the ITT population, which served for all survival analysis.
Safety was assessed in those receiving at least one dose of a
study treatment regimen, and ORR was evaluated in patients
with measurable disease. PFS and OS estimates were gener-
ated by Kaplan-Meier method and compared via log-rank
test. The Cox proportional hazards analysis was applied to
weigh outcomes of the experimental treatment against those
of the control arm, examining variables that might impact
treatment response. ORR was calculated as the proportion of
patients with complete or partial tumor responses.
The QLQ-C30 data were linearly transformed to yield
scores from 0 to 100, according to the EORTC scoring manual
[11]. The mean change in QoL score from baseline was cal-
culated separately, and analysis of variance (ANOVA) with
repeated measures was used for between-group comparison
of mean change in QoL score. All tests were 2-sided, and we
considered p-value of < 0.05 as statistically significant. All
statistics were calculated using SPSS ver. 21.0 software (IBM
Corp., Armonk, NY).
4. Ethical statement
This trial complied fully with guidelines for Good Clinical
Practice and the Declaration of Helsinki. Written informed
consent was obtained from each patient. Approval of the pro-
tocol and of any amendments was obtained from an inde-
pendent ethics committee for each site. This study was
registered with ClinicalTrials.gov (number NCT01501669).
In Hae Park, Study of Irinotecan in Metastatic Breast Cancer
Enrolled (n=233)
Randomized (n=221)
Assigned to IX (n=114)
Received  IX (n=111)
Withdrew 
consent (n=3)
Screening failure (n=9)
Withdrew consent before 
  randomization (n=3)
ITT population (n=114)
Safety population (n=111)
Response evaluable population (n=99)
Assigned to X (n=107)
Received  X (n=100)
Withdrew 
consent (n=7)
ITT population (n=107)
Safety population (n=100)
Response evaluable population (n=84)
Fig. 1. Study flowchart. ITT, intention-to-treat.
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Results
1. Baseline characteristics and study treatment
Between March 2011 and May 2016, 233 patients were 
enrolled. Of these, 114 patients were randomized to arm IX
and 107 to arm X (Fig. 1). Three patients in arm IX and seven
patients in arm X withdrew consent before proceeding to
treatment. Consequently, 211 patients received at least one
dose of assigned treatment and they were included in safety
analysis. There were no statistically significant differences
between groups in terms of age, performance status, and vis-
ceral metastasis. In arms IX and X, 54.4% and 64.5% of 
patients, had hormonal receptor positive disease. Two-thirds
of the patients received prior chemotherapy in the (neo)
adjuvant setting. The number of patients given more than
one line of chemotherapy for metastatic disease was 40
(35.1%) in arm IX and 46 (43.0%) in arm X (Table 1). Around
10% of patients received study regimens as the first-line ther-
apy for MBC. 
2. Efficacy
During a median follow-up period of 22.8 months (95% CI,
18.8 to 26.8), a total of 118 deaths had occurred, 62 (54.4%) in
arm IX and 56 (52.3%) in arm X. The two arms showed no
significant difference in median PFS (arm IX: 6.4 months;
95% CI, 4.7 to 8.1 and arm X: 4.7 months; 95% CI, 3.7 to 5.7;
p=0.21) (Fig. 2A). Median OS in the two arms were also sim-
ilar (IX: 20.4 months; 95% CI, 16.6 to 24.2 and X: 24.0 months;
95% CI, 17.1 to 30.9; p=0.63) (Fig. 2B). Those patients (n=183)
presenting with measurable disease at baseline were 
accessed for response analysis (Table 2). Objective responses
were observed in 44 patients (44.4%) of arm IX and 28 
patients (33.3%) of arm X arm, without significant difference
(p=0.30) (Table 2). 
In subgroup analysis, combination (IX) treatment showed
significant improvement in PFS for patients with the triple-
negative breast cancer (TNBC) subtype (hazard ratio [HR],
0.58; 95% CI, 0.37 to 0.91; p=0.02) (Fig. 3). Median PFS of the
TNBC subgroup in arm IX was 4.7 months (95% CI, 3.5 to
5.9), compared with 2.5 months (95% CI, 1.2 to 3.8) in arm X
(p=0.01) (Fig. 4A). However, such increase in PFS did not
Cancer Res Treat. 2019;51(1):43-52
Table 1.  The baseline patient characteristics
Characteristic IX (n=114) X (n=107) p-value
Age, median (range, yr) 50 (29-73) 49 (30-80) 0.64
ECOG PS
0 26 (22.8) 24 (22.4) 0.82
1 87 (76.3) 81 (75.7)
2 1 (0.9) 2 (1.9)
Menopausal status
Pre-menopause 30 (26.3) 32 (29.9) 0.65
Post-menopause 84 (73.7) 75 (70.1)
ER/PgR
Positive 62 (54.4) 69 (64.5) 0.13
Negative 52 (45.6) 38 (35.5)
(Neo)Adjuvant chemotherapy 89 (78.1) 77 (72.0) 0.35
Adjuvant endocrine 48 (42.1) 43 (40.2) 0.79
Visceral metastasis
Yes 66 (57.9) 63 (58.9) 0.89
No 48 (42.1) 44 (41.1)
Previous palliative endocrine therapy
Yes 38 (33.3) 44 (41.1) 0.23
No 76 (66.7) 63 (58.9)
No. of previous chemotherapies
0 13 (11.4) 13 (12.1) 0.27
1 61 (53.5) 48 (44.9)
 2 40 (35.1) 46 (43.0)
Values are presented as number (%). IX, irinotecan and capecitabine combination; X, capecitabine alone; ECOG PS, Eastern
Cooperative Oncology Group Performance Score; ER, estrogen receptor; PgR, progesterone receptor.
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lead to the prolongation of OS in this subgroup (median OS,
18.0 months; 95% CI, 13.0 to 23.0 vs. 13.2 months; 95% CI, 6.7
to 19.7; p=0.36) (Fig. 4B).
3. Safety and QoL data
Patients who received at least one dose of study treatment
were included in safety and QoL analysis. More patients in
arm IX required dose reductions or interruptions (Table 3).
The most common reasons for dose reduction or interruption
in IX arm were hematologic toxicities (85.2%, 71.1%) and
hand-foot syndrome (50.0%, 28.0%) in X arm. Permanent
therapeutic discontinuation was rare: one patient in arm IX
arm (arrhythmia) and three patients in arm X (n=1, infection;
n=2, hematologic toxicities). In arm IX, the more common
AEs included hematologic toxicities and diarrhea (Table 4).
In particular, most of neutropenia and anemia occurred in IX
arm were more than grade 2 which required dose modifica-
tion of study drugs. Although neutropenia was the most
common AE, the frequency of neutropenic fever was quite
low in IX arm (n=1, 2.6%). On the other hand, hand-foot syn-
drome of any grade was more often manifested in arm X
(53.0% vs. 31.5%). None of the AEs in either treatment arm
resulted in death. 
QoL assessments were conducted at baseline and after
every two cycles after randomization. However, data 
obtained after cycle 11 could not be reliably evaluated, with
< 10% of patients remaining in the study beyond this time
point. Significant differences in favor of arm X were noted
for diarrhea and nausea/vomiting symptom scales (p < 0.05).
The differences observed between treatment arms in other
functional scales and in the global health scale were not sig-
nificant (Fig. 5A and B). 
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Fig. 2.  Survival analysis in the intention-to-treat population. Kaplan-Meier curve for progression-free survival (PFS) (A) and
overall survival (OS) (B) between irinotecan and capecitabine combination (IX) and capecitabine alone (X). mPFS, median
PFS; mOS, median OS; CI, confidence interval. 
Table 2.  Tumor responses for patients with measurable
disease 
IX (n=99) X (n=84) p-value
CR 4 (4.0) 1 (1.2)
PR 40 (40.4) 27 (32.1)
SD 30 (30.3) 26 (31.0)
PD 16 (16.2) 22 (26.2)
Not known 9 (9.1) 8 (9.5)
ORR 44 (44.4) 28 (33.3) 0.30
Values are presented as number (%). IX, irinotecan and
capecitabine combination; X, capecitabine alone; CR, com-
plete response; PR, partial response; SD, stable disease;
PD, progressive disease; ORR, objective response rate
(CR+PR).
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Favours treatment of IX Favours treatment of X
0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.8 2.0
Age
    ≥ 45 yr
    < 45 yr
Subtype
    TNBC
    Non-TNBC
Visceral involvement
    No
    Yes
Target lesion
    No
    Yes
Previous regimens
    0-1
    ≥ 2
HR (95% CI)
0.73 (0.52-1.03)
1.09 (0.67-1.78)
0.58 (0.37-0.91)
0.83 (0.57-1.20)
0.81 (0.52-1.28)
0.84 (0.58-1.20)
0.86 (0.39-1.90)
0.80 (0.59-1.08)
0.85 (0.59-1.22)
0.85 (0.54-1.33)
p-value
0.07
0.73
0.02
0.32
0.37
0.33
0.71
0.14
0.37
0.58
Fig. 3. The forest plots of progression-free survival in subgroups stratified by clinical factors. IX, irinotecan and capecitabine
combination; X, capecitabine; HR, hazard ratio; CI, confidence interval; TNBC, triple negative breast cancer. 
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Fig. 4.  Survival analysis in the triple negative breast cancer subgroup. Kaplan-Meier curve for progression-free survival
(PFS) (A) and overall survival (OS) (B) between irinotecan and capecitabine combination (IX) and capecitabine alone (X).
mPFS, median PFS; mOS, median OS; CI, confidence interval.
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Discussion
In general, combination therapy for MBC showed pro-
longed PFS with higher response rate compared to
monotherapy, though such beneficial effects did not result
in improved OS [15-18]. In this phase III study, the addition
of irinotecan to capecitabine (IX) did not show the superior
clinical efficacies to capecitabine monotherapy (X) in patients
with MBC previously exposed to anthracycline and taxane
based treatment. The study was designed based on the 
assumption that combination treatment (IX) would prolong
PFS 2.0 months beyond the 4.0-month PFS of monotherapy
(X). In our results, the PFS of arm IX was 6.4 months (95%
CI, 4.7 to 8.1), and that of arm X was 4.7 months (95% CI, 3.7
to 5.7). For overall response rate, IX showed numerically
higher response rate, however it did not reach statistical sig-
nificance (44.4% vs. 33.3%, p=0.30). There are several possible
explanations for the failure of this study. First, the number
of patients with estrogen receptor– or progesterone recep-
tor–positive disease in arm X arm was higher (64.5% vs.
54.4%, p=0.13), though it was not statistically significant.
Such imbalance between two groups may have had caused
the better PFS of arm X than expected. Second, the dose 
reductions and interruptions due to more frequent and 
severe hematologic toxicities of the combination treatment
In Hae Park, Study of Irinotecan in Metastatic Breast Cancer
Table 3.  Dose modification of study drugs according to AEs
IX (n=111) X (n=100)
Dose reduction 61 (54.9) 34 (34.0)
Hematologic AE 52 (85.2) 9 (26.5)
Hand-foot syndrome 12 (23.1) 17 (50.0)
Diarrhea 4 (6.6) 0 (
Dose interruption 38 (34.2) 25 (25.0)
Hematologic AE 27 (71.1) 14 (56.0)
Hand-foot syndrome 5 (13.2) 7 (28.0)
Neutropenic fever 1 (2.6) 1 (4.0)
Diarrhea 1 (2.6) 1 (4.0)
Treatment discontinuation 1 (0.9) 3 (3.0)
1 (arrhythmia) 1 (infection), 2 (hematologic AE)
Values are presented as number (%). AE, adverse events; IX, irinotecan and capecitabine combination; X, capecitabine alone.
IX (n=111) X (n=100)
p-value
Grade 1-2 Grade 3-4 Grade 1-2 Grade 3-4
Hematologic AE
Neutropenia 26 (23.4) 44 (39.6) 7 (7.0) 9 (9.0) < 0.001
Anemia 3 (2.7) 16 (14.4) 10 (10.0) 1 (1.0) < 0.001
Thrombocytopenia 7 (6.3) 0 ( 4 (4.0) 0 ( 0.45
Non-hematologic AE
Hand-foot syndrome 33 (29.7) 2 (1.8) 49 (49.0) 4 (4.0) 0.007
Diarrhea 46 (41.4) 3 (2.7) 29 (29.0) 1 (1.0) 0.012
Nausea/Vomiting 61 (54.9) 0 ( 36 (36.0) 2 (2.0) 0.03
Liver function abnormality 2 (1.8) 0 ( 7 (7.0) 1 (1.0) 0.098
Paronychia 2 (1.8) 0 ( 4 (4.0) 1 (1.0) 0.36
Edema 9 (8.1) 0 ( 5 (5.0) 0 ( 0.37
Asthenia 3 (2.7) 0 ( 5 (5.0) 0 ( 0.38
Insomnia 15 (13.5) 0 ( 7 (7.0) 0 ( 0.12
Table 4. Treatment related adverse events in both arms
Values are presented as number (%). IX, irinotecan plus capecitabine arm; X, capecitabine alone arm; AE, adverse events. 
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Fig. 5.  Quality of life measurement. (A) The difference between baseline and each time point in global health and functional
subscales. Positive values meant improved state compared with baseline. (B) The change in symptom subscales from baseline.
In contrast to functional subscales, negative values meant improved state. IX, irinotecan and capecitabine combination; X,
capecitabine. *p < 0.05.
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may have made it difficult to maintain adequate dose inten-
sities of both irinotecan and capecitabine in this group. 
Even though it was a subgroup analysis, results of the
TNBC subgroup were intriguing. There have been few data
regarding the benefits of combination therapy according to
hormone receptor status. Similarly to our study, another
phase III trial comparing ixabepilone plus capecitabine with
single-agent capecitabine has demonstrated the superiority
of combination treatment in a TNBC patient subgroup (HR,
0.64; 95% CI, 0.48 to 0.84) [18], whereas patients with hor-
mone receptor–positive disease did not receive benefits from
combination therapy (HR, 0.96; 95% CI, 0.80 to 1.14). Consid-
ering the more potent cytotoxic effects of combination ther-
apy, it may be more reasonable to target hormone receptor
negative-disease, which progresses rapidly with early drug
resistance. Additionally, there was a tendency for OS 
improvement with irinotecan combination treatment in
TNBC subgroup in this study, which was not adequately
powered. 
There were some concerns regarding safety of IX combi-
nation. Although most of the toxicities were manageable,
neutropenia was the most pronounced toxicity that was 
responsible for frequent dose interruptions and delays. In 
addition, gastrointestinal symptoms such as diarrhea, nau-
sea, and vomiting had significantly worse effects on QoL. In
an earlier study, Perez et al. [7] has shown that weekly
irinotecan is more tolerable and effective than every 3 weeks
treatment. Although we did administer irinotecan on a
weekly basis, the degree of toxicity seemed to be worse as
combined with capecitabine. 
Recently, the result of phase III clinical trial (BEACON)
which compared oral irinotecan agent, etirinotecan pegol
with treatment of physician’s choice in patients with HER2
negative MBC was reported [19]. Etirinotecan pegol is 
designed to improve tissue distribution and reduce the tox-
icities of SN38, the active metabolite of irinotecan [20]. The
toxicity profile of etirinotecan pegol was comparable to that
of control arm, despite worse gastrointestinal symptoms 
( grade 3 diarrhea 10% vs. 1%) [19,21]. Although the study
did not demonstrate an improvement in OS for etirinotecan
pegol arm compared to control arm, subgroup analysis
showed prolonged survival in patients with liver or brain
metastasis, more aggressive disease [22]. Irinotecan may
have promise for more challenging diseases such as TNBC
or those with visceral metastasis, as inferred from BEACON
trial and our study. 
In summary, irinotecan and capecitabine combination did
not prove clinically superior to capecitabine alone as treat-
ment of HER2-negative anthracycline- and taxane-pretreated
MBC. Even though more AEs were found in combination
treatment arm, most cases were tolerable and manageable.
In view of the unmet need for effective drugs in highly 
refractory disease, irinotecan based chemotherapy could
offer some benefits to patients with TNBC based on our sub-
group analysis. Further clinical studies will be needed for
irinotecan based treatment for this subgroup of patients. In
addition, the reasonable approach to mitigate irinotecan tox-
icities should be planned as part of proactive supportive care.  
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